Government/Legal Affairs

In February 2026, Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) introduced the Break Up Big Medicine Act (S. 3822). The bipartisan legislation, referred to the Senate Judiciary Committee, aims to prohibit pharmacy benefit managers (PBMs), health insurers, and prescription drug or medical device wholesalers from being under common ownership with certain medical service providers or provider groups, including in-patient or outpatient pharmacies.

The undersigned organizations representing health care clinicians, public health, older adults, patients, family caregivers, consumers, physicians, and other health care providers support plaintiffs in American Academy of Pediatrics et al. v. Kennedy Jr., et al. (including the American Academy of Pediatrics, American College of Physicians, American Public Health Association, Infectious Diseases Society of America, the Society for Maternal-Fetal Medicine, Massachusetts Public Health Alliance, and the Massachusetts Chapter of the AAP).

AMCP commends ACIP’s commitment to regularly reviewing the scientific evidence underlying national immunization recommendations. We recognize the importance of maintaining guidance that is both scientifically rigorous and operationally feasible across diverse care settings. In that spirit, we offer the following comments on the Committee’s ongoing consideration of vaccine safety and the hepatitis B vaccine birth-dose recommendation.

Just after midnight on the morning of Aug. 7, President Trump’s sweeping “reciprocal” tariffs took effect on dozens of international trading partners, marking another dramatic escalation of the administration’s “America First” trading policy.

AMCP comments on Trump Administration demands for manufacturers to take action on Most-Favored-Nation pricing scheme

Immediately following the 2024 presidential election, GOP leaders in the House of Representatives, Senate, and incoming administration expressed a desire to use a procedural tool to advance partisan spending legislation.

AMCP and its members advocate for bipartisan legislation that eliminates bureaucratic barriers to high-quality, innovative therapies, while lowering the bill footed by patients, families, government, employers, and other healthcare payers.